8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  May 16, 2013

Emmaus Life Sciences, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	000-53072	41-2254389
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of Incorporation)

20725 S. Western Avenue, Suite 136, Torrance, CA 90501

(Address, including zip code, off principal executive offices)

Registrant’s telephone number, including area code   310-214-0065

____________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01                      Other Events.

On May 16, 2013, Emmaus Life Sciences, Inc., announced that the Superior Court of Delaware granted in full its motion for summary judgment in the company’s lawsuit against AFH Holding & Advisory, LLC (“AFH”) and Amir Heshmatpour. The announcement was set forth in a press release attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01                      Financial Statements and Exhibits.

Exhibit No.                      Description

Exhibit 99.1                      Press release dated May 16, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Emmaus Life Sciences, Inc.
Date: May 17, 2013
	By:	/s/ Peter Ludlum
	Name:	Peter Ludlum
	Title:	Chief Financial Officer

EX-3.1

EXHIBIT 99.1

Emmaus Life Sciences Wins Sweeping Summary Judgment Victory

In Suit Against AFH Holding & Advisory and Amir Heshmatpour

TORRANCE, Calif., May 16, 2013 – Emmaus Life Sciences, Inc., a company dedicated to the discovery, development and commercialization of innovative and cost effective treatments and therapies for rare diseases, today announced that the Superior Court of Delaware granted in full its motion for summary judgment in the company’s lawsuit against AFH Holding & Advisory, LLC (“AFH”) and Amir Heshmatpour.

The court declared as a matter of law that Emmaus has properly canceled all shares of Emmaus common stock held by AFH, that AFH and Mr. Heshmatpour must return to Emmaus all stock certificates representing such shares, and that the letter of intent between Emmaus and AFH pursuant to which such shares were issued has been properly canceled. Arguments to the contrary by AFH and Mr. Heshmatpour were characterized by the court as “patently unreasonable” and “contrary to the unambiguous terms” of the letter of intent.

Emmaus’s fraud claims against AFH and Mr. Heshmatpour remain to be litigated. As part of its decision, the court ruled that Mr. Heshmatpour “is not immune from individual personal liability if he is found to have engaged in fraudulent conduct.”

“We are very pleased with the court’s ruling today,” said Yutaka Niihara, M.D., MPH, President and CEO of Emmaus. “It vindicates our hard-fought effort to end AFH’s interference with Emmaus. We look forward to putting this lawsuit behind us and continuing to focus on our core business.”

About Emmaus Life Sciences

Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.
 

For more information, please visit www.emmauslifesciences.com.
 

Contacts:
 

Media:

Lori Teranishi for Emmaus Life Sciences, Inc.

415-981-1964

Investors:

Matt Sheldon for Emmaus Life Sciences, Inc.

310-279-5975

msheldon@pondel.com

# # #